Literature DB >> 3732080

Bronchopulmonary infection due to B. catarrhalis. Clinical features and therapeutic response.

D T McLeod, F Ahmad, M J Croughan, M A Calder.   

Abstract

A study was made of the clinical features and therapeutic response of 144 patients from whose sputum Branhamella catarrhalis was isolated. Typically, features of bronchopulmonary infection with cough productive of moderate amounts of purulent sputum, fever and dyspnoea were present. Of 74 patients who were infected in the community, 50 required hospital admission. Nosocomial infection occurred in the remaining 70 patients. Most patients had chronic pulmonary diseases or carcinoma bronchus; pneumonia occurred in 12 patients. Acute tracheobronchitis developed in 4 healthy non-smokers after viral illnesses. B. catarrhalis contributed to the death of 8 patients. Overall, 59% of isolates produced beta-lactamase but the proportion had risen to 70% by the end of the study; half of these were community acquired. 41% of patients who were treated initially with ampicillin did not respond. Clavulanic acid plus amoxycillin, co-trimoxazole, erythromycin, tetracycline, cefuroxime and cefotaxime are useful alternative antibiotics. All strains of B. catarrhalis were resistant to trimethoprim.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732080     DOI: 10.2165/00003495-198600313-00023

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  Remarks ON THE CLINICAL AND BACTERIOLOGICAL ASPECTS OF AN EPIDEMIC SIMULATING INFLUENZA, WHICH HAS RECENTLY OCCURRED IN THE EAST HERTS DISTRICT.

Authors:  R A Dunn; M H Gordon
Journal:  Br Med J       Date:  1905-08-26

2.  Fatal Neisseria (Branhamella) catarrhalis pneumonia in an immunodeficient host.

Authors:  D J McNeely; C S Kitchens; R M Kluge
Journal:  Am Rev Respir Dis       Date:  1976-08

3.  Antimicrobial susceptibility of Branhamella catarrhalis isolates from bronchopulmonary infections.

Authors:  F Ahmad; D T McLeod; M J Croughan; M A Calder
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

4.  Branhamella catarrhalis infection of the lower respiratory tract: reliable diagnosis by sputum examination.

Authors:  P E Thornley; J Aitken; C J Drennan; J MacVicar; N J Slevin
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-27

5.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

6.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

7.  Branhamella catarrhalis as an indirect pathogen.

Authors:  J K Wardle
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Branhamella catarrhalis pneumonia and immunoglobulin abnormalities: a new association.

Authors:  L A Diamond; B Lorber
Journal:  Am Rev Respir Dis       Date:  1984-05

9.  Bronchopulmonary infection due to Branhamella catarrhalis.

Authors:  D T McLeod; F Ahmad; J T Power; M A Calder; A Seaton
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12

10.  Branhamella catarrhalis pneumonia: report of two cases and review of the literature.

Authors:  G Srinivasan; M J Raff; W C Templeton; S J Givens; R C Graves; J C Melo
Journal:  Am Rev Respir Dis       Date:  1981-05
View more
  7 in total

Review 1.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 3.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

4.  Epidemiological typing of Moraxella catarrhalis by using DNA probes.

Authors:  D Beaulieu; S Scriver; M G Bergeron; D E Low; T R Parr; J E Patterson; A Matlow; P H Roy
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

5.  Serum antibody response to proteins of Moraxella (Branhamella) catarrhalis in patients with lower respiratory tract infection.

Authors:  J J Christensen; J Renneberg; B Bruun; A Forsgren
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

6.  Characterization of an antigenically conserved heat-modifiable major outer membrane protein of Branhamella catarrhalis.

Authors:  J Sarwar; A A Campagnari; C Kirkham; T F Murphy
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  Characterization of cell-bound papain-soluble beta-lactamases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens.

Authors:  I Eliasson; C Kamme; M Vang; S G Waley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.